Pharma News

Novartis starts building a $23bn research hub in San Diego. The 466,000ft² facility targets oncology, neuroscience, and gene therapies, opening in 2029.

Enanta Pharmaceuticals to present EDP-978 KIT inhibitor data for Type 2 immune diseases at the 2026 AAAAI Meeting. Learn about potent mast cell treatments.

NanoViricides files for US FDA Orphan Drug Designation for NV-387. A breakthrough broad-spectrum antiviral targeting the global measles resurgence.

Cedars-Sinai study shows senolytics eliminate 70% of 'zombie' cells. Learn how new senosensitizers target resistant cells to combat aging diseases and cancer.

Lupin announced U.S. FDA granted Orphan Drug Designation to mexiletine hydrochloride for the treatment of myotonic disorders.

San Diego biotech Neomorph begins first clinical trial for molecular glue NEO-811 to treat clear cell renal cell carcinoma, putting claim to the test.

Alteogen's once-monthly obesity drug showed weight loss matching retatrutide and less yo-yo regain in preclinical tests, applying NexP platform.

Apotex and Grünenthal finalised a licensing agreement granting Apotex exclusive Canadian rights to Nebido, a long-acting injectable testosterone therapy.

Ohio State and IIT Madras researchers developed PURE, an AI framework using reinforcement learning to generate drug-like molecules for synthesis.

CNIO study shows triple KRAS inhibition cures pancreatic cancer in mice, but experts caution rigorous clinical trials needed to assess efficacy in humans.

SEQSTER and Praxis expand partnership to accelerate clinical trials and RWE generation for CNS disorders like epilepsy using real-world patient data.

UMSOM and ENA Respiratory launch Phase 2 trial of INNA-051, a TLR2/6 agonist intranasal spray to prevent respiratory viruses in adults.